In addition, Cav-1 might also regulate glucose uptake and mediate the endocytosis of urinary albumin; therefore, it is considered a potential therapeutic target for DKD (Van Krieken and Krepinsky, 2017). This evidence concerns the gene CAV1 and diabetic kidney disease.